Home › Mieloma multiplo › Illinois
Studi clinici su Mieloma multiplo nello stato di Illinois
31 studi su Mieloma multiplo cercano partecipanti presso sedi nello stato di Illinois.
Città nello stato di Illinois
- Chicago22 studi
- Cicero6 studi
- Evanston4 studi
- Waukegan4 studi
- Springfield4 studi
- Aurora3 studi
- Decatur3 studi
- Galesburg3 studi
- Bloomington3 studi
- North Peoria3 studi
- Peoria3 studi
Testo ufficiale dello studio (inglese)
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- e altri 13
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT06948084A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
- University of Chicago Medical Center /ID# 278863, Chicago
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT07409246A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Chicago
- Research Site, Park Ridge
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT07391657A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Chicago Medical Center, Chicago
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT04973605A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- University Of Illinois Medical Center, Chicago
- Loyola University Medical Center, Maywood
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05552222A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- City of Hope Chicago, Zion
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07258511A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Northwestern University, Chicago
- University of Chicago, Chicago
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT05201781A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Rush University System for Health, Chicago
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07518186Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT05789303TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Cancer Treatment Centers of America-Chicago, Chicago
In reclutamentoFase 2
Età 12 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT02693535Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT06297226Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
- University of Illinois at Chicago, Chicago
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 ago 2026 · NCT05344833MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Endeavor Health - Swedish Hospital, Chicago
- Endeavor Health - Evanston Hospital, Evanston
- Endeavor Health - Glenbrook Hospital Ambulatory Care Center, Glenview
- e altri 6
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 ago 2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- OSF Saint Anthony's Health Center, Alton
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- e altri 40
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 19 ago 2026 · NCT04566328AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Chicago
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Chicago
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 ago 2026 · NCT07764978A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Loyola University Medical Center, Maywood
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 12 ago 2026 · NCT07280013Mosaic Trial for Stem Cell Transplant Recipients
- Northwestern University Feinberg School of Medicine, Chicago
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 ago 2026 · NCT06960993Moving Forward With Myeloma: A Lifestyle Intervention for Individuals With Multiple Myeloma
- Loyola University Chicago, Maywood
In reclutamento
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 lug 2026 · NCT07236502A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Hope And Healing Cancer Services /ID# 268536, Hinsdale
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 lug 2026 · NCT05650632Integrated Cancer Repository for Cancer Research
- Rush-Copley Cancer Care Center, Aurora
- Rush-Copley Healthcare Center, Yorkville
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età da 19 a 110 · Tutti i sessi · Aggiornato il 29 giu 2026 · NCT02012699Personalized Autologous Transplant for Multiple Myeloma
- University Illinois Chicago, Chicago
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 giu 2026 · NCT04483206Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Saint Anthony's Health, Alton
- Rush - Copley Medical Center, Aurora
- Saint Joseph Medical Center, Bloomington
- e altri 41
In reclutamentoFase 3
Tutte le età · Tutti i sessi · Aggiornato il 10 giu 2026 · NCT05561387Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- University of Chicago, Chicago
- University of Illinois Medical Center at Chicago, Chicago
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 giu 2026 · NCT05243797Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- University of Chicago, Chicago
In reclutamentoFase 1
Età 13 e oltre · Tutti i sessi · Aggiornato il 5 mag 2026 · NCT04771572Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
- University of Chicago Medical Center, Chicago
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 apr 2026 · NCT05862012Hypofractionation (Radiation) Trial for Multiple Myeloma
- The University of Chicago Comprehensive Cancer Center, Chicago
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 mar 2026 · NCT06270888A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Northwestern, Chicago
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 24 mar 2026 · NCT04988555Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
- Northshore University Health System, Evanston
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 feb 2026 · NCT05974150A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
- City of Hope at Chicago, Zion
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 feb 2026 · NCT07225738Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD
- University of Illinois Cancer Center, Chicago
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 dic 2025 · NCT05192122Fonte: ClinicalTrials.gov, dati recuperati il 2 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.